Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...
In a study of around 228,000 people in Sweden who had alcohol use disorder, researchers found that people who were taking a ...
A new weight loss drug target may help reduce appetite and burn calories without causing sickness, research suggests. The ...
Pemvidutide is a promising GLP-1/glucagon dual receptor agonist that focuses on fundamental metabolic processes to stimulate ...
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...
Early studies show a drug can effectively 'switch on' particular cells within the nervous system that play an important role ...
Ro details dietary choices that may help Wegovy's capacity to regulate appetite and foster a healthier weight as well as ...
Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback